Roivant Sciences (ROIV) Other Non-Current Liabilities (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Other Non-Current Liabilities came in at $38.7 million in Q1 2026, up 5611.96% on a QoQ basis from $677000.0 in Q4 2025.
Roivant Sciences (ROIV) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Other Non-Current Liabilities data on file, last reported at $38.7 million in Q1 2026.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $38.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.7 million (changed N/A YoY) and the FY2026 annual result came in at $38.7 million, changed N/A from the prior year.
- Other Non-Current Liabilities climbed to $38.7 million in Q1 2026, from $677000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $38.7 million in Q1 2026 to a low of $170000.0 in Q3 2025.
- A 5-year average of $9.3 million and a median of $4.8 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 168.37% — and 2024, when it slumped 94.3%.
- Tracing ROIV's Other Non-Current Liabilities over 5 years: stood at $21.5 million in 2022, then slumped by 79.38% to $4.4 million in 2023, then slumped by 93.07% to $307000.0 in 2024, then surged by 120.52% to $677000.0 in 2025, then surged by 5611.96% to $38.7 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $38.7 million (Q1 2026), $677000.0 (Q4 2025), and $170000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.25 Mn |
| Mar 31, 2026 | 38.67 Mn |
| Dec 31, 2025 | 677,000.00 |
| Sep 30, 2025 | 170,000.00 |
| Jun 30, 2025 | 228,000.00 |
| Dec 31, 2024 | 307,000.00 |
| Sep 30, 2024 | 295,000.00 |
| Jun 30, 2024 | 1.66 Mn |
| Mar 31, 2024 | 2.49 Mn |
| Dec 31, 2023 | 4.43 Mn |
| Sep 30, 2023 | 5.18 Mn |
| Jun 30, 2023 | 16.90 Mn |
| Mar 31, 2023 | 17.03 Mn |
| Dec 31, 2022 | 21.48 Mn |
| Sep 30, 2022 | 9.10 Mn |
| Jun 30, 2022 | 8.16 Mn |
| Mar 31, 2022 | 21.92 Mn |
| Dec 31, 2021 | 8.18 Mn |
| Sep 30, 2021 | 8.19 Mn |
| Jun 30, 2021 | 8.19 Mn |